Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals

Journal of Medical Virology

Volumn 88, Issue 10, 2016, Pages 1659-1671

  Coppola, Nicola ^a   Minichini, Carmine ^a   Starace, Mario ^a   Sagnelli, Caterina ^a   Sagnelli, Evangelista ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

chronic hepatitis C; DAAs; HCV infection; NS3 4A; NS5A; NS5B; viral mutations

Indexed keywords

ANTIVIRUS AGENT; ASUNAPREVIR; BECLABUVIR; BOCEPREVIR; DACLATASVIR; DASABUVIR; DIRECTLY ACTING ANTIVIRAL; ELBASVIR; GRAZOPREVIR; LEDIPASVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5A INHIBITOR; NONSTRUCTURAL PROTEIN 5B; NONSTRUCTURAL PROTEIN 5B INHIBITOR; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; VANIPREVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; CHRONIC HEPATITIS C; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; REVIEW; VIRION; VIRUS MUTANT; VIRUS MUTATION; VIRUS STRAIN;

EID: 84979911433     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.24527     Document Type: Review

References (108)

1. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P. 2014. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370:1889–1898.
2. Italian Association for the Study of the Liver; Italian Society of Infectious, Tropical Diseases; Italian Society for the Study of Sexually Transmitted Diseases. 2010. Practice guidelines for the treatment of hepatitis C: Recommendations from an AISF/SIMIT/SIMAST expert opinion meeting. Dig Liv Dis 42:81–91.
3. Aissa Larousse J, Trimoulet P, Recordon-Pinson P, Papuchon J, Azzouz MM, Ben Mami N, Cheikh I, Triki H, Fleury H. 2014. Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia. J Med Virol 86:1350–1359.
4. Aissa Larousse J, Trimoulet P, Recordon Pinson P, Tauzin B, Azzouz MM, Mami NB, Cheikh I, Triki H, Fleury H. 2015. Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia. Virol J 12:84.
5. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Ikeda K, Kumada H. 2014. Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in HCV genotype 1b. J Med Virol 86:1314–1322.
6. Akuta N, Suzuki F, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Saitoh S, Kobayashi M, Ikeda K, Kumada H. 2015. Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b. J Med Virol 87:609–618.
7. Aloia AL, Eyre NS, Black S, Bent SJ, Gaeguta A, Guo Z, Narayana SK, Chase R, Locarnini S, Carr JM, Howe JA, Beard MR. 2015. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations. Antivir Ther 20:271–280.
8. Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, Takemoto D, Dondero E, Kwong AD, Picchio G, Kieffer TL. 2013. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol 87:1544–1553.
9. Bartolini B, Selleri M, Garbuglia AR, Giombini E, Taibi C, Lionetti R, D'Offizi G, Capobianchi MR. 2015. HCV NS3 quasispecies in liver and plasma and dynamics of telaprevir-resistant variants in breakthrough patients assessed by UDPS: A case study. J Clin Virol 72:60–65.
10. Beloukas A, King S, Childs K, Papadimitropoulos A, Hopkins M, Atkins M, Agarwal K, Nelson M, Geretti AM. 2015. Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK. Clin Microbiol Infect 21:1033–1339.
11. Boglione L, De Nicolò A, Cardellino CS, Ruggiero T, Ghisetti V, Cariti G, Di Perri G, D'Avolio A. 2015. Relationship between the early boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy. Clin Microbiol Infect 21:205.e1.
12. Buti M, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, Gilbert C, Palcza J, Howe AY, DiNubile MJ, Robertson MN, Wahl J, Barr E, Forns X. 2016. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: Final 24-week results from C-SALVAGE. Clin Infect 62:32–36.
13. Cao Y, Zhang Y, Bao Y, Zhang R, Zhang X, Xia W, Wu H, Xu X. 2015. Naturally occurring HCV protease inhibitors resistance-associated mutations among chronic hepatitis C genotype 1b patients with or without HIV coinfection. Hepatol Res In press. DOI: 10.1111/hepr.12590
14. Cento V, Mirabelli C, Salpin R, Dimonte S, Artese A, Costa G, Mercurio F, Svicher V, Parrotta L, Bertoli A, Ciotti M, Di Paolo D, Sarrecchia C, Andreoni M, Alcaro S, Angelico M, Perno CF, Ceccherini-Silberstein F. 2012. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS ONE 7:e39652.
15. Choo QL, Kuo G, Weiner, Overby LR, Bradley DW, Houghton M. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral-hepatitis genome. Science 244:359–362.
16. Chopp S, Vanderwall R, Hult A, Klepser M. 2015. Simeprevir and sofosbuvir for treatment of hepatitis C infection. Am J Health Syst Pharm 72:1445–1455.
17. Coppola N, Pisaturo M, Tonziello G, Sagnelli C, Sagnelli E, Angelillo IF. 2012. Efficacy of Pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: A meta-analysis. BMC Infect Dis 357:2334–12. DOI: 10.1186/1471
18. Coppola N, Zampino R, Sagnelli C, Bellini G, Marrone A, Stanzione M, Capoluongo N, Boemio A, Minichini C, Adinolfi LE, Maione S, Del Giudice EM, Sagnelli E, Rossi F. 2014a. Cannabinoid receptor 2-63 QQ variantis associated with persistently normal aminotransferase serum levels in chronic hepatitis C. PLoS ONE 9:e99450.
19. Coppola N, Pisaturo M, Sagnelli C, Sagnelli E, Angelillo IF. 2014b. Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: A meta-analysis on the role of response predictors. PLoS ONE 9:e94542.
20. Coppola N, Zampino R, Cirillo G, Stanzione M, Macera M, Boemio A, Grandone A, Pisaturo M, Marrone A, Adinolfi LE, Sagnelli E, Miraglia Del Giudice E. 2015a. TM6SF2 E167 K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism. Liver Int 35:1959–1963.
21. Coppola N, Onorato L, Pisaturo M, Macera M, Sagnelli C, Martini S, Sagnelli E. 2015b. Role of occult hepatitis B virus infection in chronic hepatitis C. World J Gastroenterol 21:11931–11940.
22. Coppola N, Pisaturo M, Zampino R, Macera M, Sagnelli C, Sagnelli E. 2015c. Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals. World J Gastroenterol 21:10749–10759.
23. Costantino A, Spada E, Equestre M, Bruni R, Tritarelli E, Coppola N, Sagnelli C, Sagnelli E, Ciccaglione AR. 2015. Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C. Virol J 12:186. DOI: 10.1186/s12985-015-0414-1
24. Cuypers L, Li G, Libin P, Piampongsant S, Vandamme AM, Theys K. 2015. Genetic diversity and selective pressure in hepatitis C virus genotypes 1-6: Significance for direct-acting antiviral treatment and drug resistance. Viruses 7:5018–5039.
25. Dierynck I, Ghys A, Witek J, Luo D, Janssen K, Daems B, Picchio G, Buti M, De Meyer S. 2014. Incidence of virological failure and emergence of resistance with twice-daily vs every 8-h administration of telaprevir in the OPTIMIZE study. J Viral Hepat 21:835–842.
26. Donaldson EF, Harrington PR, O'Rear JJ, Naeger LK. 2014. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for Sofosbuvir. Hepatology 61:56–65.
27. Dvory-Sobol H, Wyles D, Ouyang W, Chodavarapu K, McNally J, Cheng W, Shafran S, Mangia A, Schwabe C, Miller MD, Mo H. 2015. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. J Hepatol 62.
28. European Association for the Study of the Liver. 2011. EASL clinical practice guidelines: Management of hepatitis C virus infection. J Hepatol 55:245–264.
29. European Association for Study of Liver. 2014. EASL clinical practice guidelines: Management of hepatitis C virus infection. J Hepatol 60:392–420.
30. Ezat AA, El-Bialy NS, Mostafa HI, Ibrahim MA. 2014. Molecular docking investigation of the binding interactions of macrocyclic inhibitors with HCV NS3 protease and its mutants (R155 K, D168A and A156V). Protein J 33:32–47.
31. Fridell RA, Wang C, Sun JH, O'Boyle DR, Nower P, Valera L, Qiu D, Roberts S, Huang X, Kienzle B, Bifano M, Nettles RE, Gao M. 2011. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: In vitro and in vivo correlations. Hepatology 54:1924–1935.
32. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM. 2013. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 368:34–44.
33. Gentile I, Borgia F, Buonomo AR, Castaldo G, Borgia G. 2013. A novel promising therapeutic option against hepatitis C virus: An oral nucleotide NS5B polymerase inhibitor sofosbuvir. Curr Med Chem 20:3733–3742.
34. Gentile I, Borgia F, Coppola N, Buonomo AR, Castaldo G, Borgia G. 2014a. Daclatasvir: The first of a new class of drugs targeted against hepatitis C virus NS5A. Curr Med Chem 21:1391–1404.
35. Gentile I, Coppola N, Buonomo AR, Zappulo E, Borgia G. 2014b. Investigational NS polymerase inhibitors and their use in treating HCV. Expert Opin Investig Drugs 21:1–13.
36. Ghany MG, Strader DB, Thomas DL, Seef IL. 2009. Diagnosis, management and treatment of hepatitis C: An update. Hepatology 49:1335–1374.
37. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. 2014. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:S45–S57.
38. Hanoulle X, Verdegem D, Badillo A, Wieruszeski JM, Penin F, Lippens G. 2009. Domain 3 of non-structural protein 5A from hepatitis C virus is natively unfolded. Biochem Biophys Res Commun 381:634–638.
39. Herzer K, Papadopoulos-Köhn A, Walker A, Achterfeld A, Paul A, Canbay A, Timm J, Gerken G. 2015. Daclatasvir, simeprevir and ribavirin as a promising interferon-free triple regimen for HCV recurrence after liver transplant. Digestion 91:326–333.
40. Hutchison C, Kwong A, Ray S, Struble K, Swan T, Miller V. 2014. Accelerating drug development through collaboration: The hepatitis C drug development advisory group. Clin Pharmacol Ther 96:162–165.
41. Itakura J, Kurosaki M, Takada H, Nakakuki N, Matsuda S, Gondou K, Asano Y, Hattori N, Itakura Y, Tamaki N, Yasui Y, Suzuki S, Hosokawa T, Tsuchiya K, Nakanishi H, Takahashi Y, Maekawa S, Enomoto N, Izumi N. 2015. Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to IL28B genotype and are sensitive to interferon-based therapy. Hepatol Res 45:E115–121.
42. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. 2011. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364:2405–2416.
43. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR; POSITRON Study; FUSION Study. 2013. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368:1867–1877.
44. Jacobson IM, Asante-Appiah E, Wong P, Black TA, Howe AY, Wahl J, Robertson M, Nguyen BT, Shaughnessy M, Hwang P, Barr E, Hazuda D. 2015. Prevalence and impact of baseline NSA resistance associated variants (RAVs) on the efficacy of elbasvir/grazoprevir (EBR/GZR) against GT1a infection. Hepatology 62: abstract LB-22.
45. Jensen SB, Serre SB, Humes DG, Ramirez S, Li YP, Bukh J, Gottwein JM. 2015. Substitutions at hepatitis C virus genotypes 2–6 NS3 residues 155, 156, or 168 induce complex patterns of protease inhibitor resistance. Antimicrob Agents Chemother 59:7426–7436.
46. Jiang M, Mani N, Lin C, Ardzinski A, Nelson M, Reagan D, Bartels D, Zhou Y, Nicolas O, Rao BG, Müh U, Hanzelka B, Tigges A, Rijnbrand R, Kieffer TL. 2013. In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir. Antimicrob Agents Chemother 57:6236–6245.
47. Kai Y, Hikita H, Tatsumi T, Nakabori T, Saito Y, Morishita N, Tanaka S, Nawa T, Oze T, Sakamori R, Yakushijin T, Hiramatsu N, Suemizu H, Takehara T. 2015. Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice. J Gastroenterol 50:1145–1151.
48. Karino Y, Toyota J, Ikeda K, Suzuki F, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Hernandez D, Yu F, McPhee F, Kumada H. 2013. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 58:646–654.
49. Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, DeGoey D, Kati W, Campbell A, Williams L, Xie W, Setze C, Molla A, Collins C, Pilot-Matias T. 2015a. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother 59:979–987.
50. Krishnan P, Tripathi R, Schnell G, Reisch T, Beyer J, Dekhtyar T, Irvin M, Xie W, Larsen L, Podsadecki T, Pilot-Matias T, Collins C. 2015b. Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens. J Hepatol 62: abstract O057.
51. Kwo P, Gitlin N, Nahass R, Bernstein D, Rojter S, Schiff E, Davis M, Ruane PJ, Younes Z, Kalmeijer R, Peeters M, Lenz O, Fevery B, Rosa G, Scott J, Sinha R, Witek J. 2015. A phase 3, randomised, open-label study to evaluate the efficacy and safety of 12 and 8 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and—Experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1. J Hepatol 62: abstract LP14.
52. Larrat S, Vallet S, David-Tchouda S, Caporossi A, Margier J, Ramière C, Scholtes C, Haïm-Boukobza S, Roque-Afonso AM, Besse B, André-Garnier E, Mohamed S, Halfon P, Pivert A, LeGuillou-Guillemette H, Abravanel F, Guivarch M, Mackiewicz V, Lada O, Mourez T, Plantier JC, Baazia Y, Alain S, Hantz S, Thibault V, Gaudy-Graffin C, Bouvet D, Mirand A, Henquell C, Gozlan J, Lagathu G, Pronier C, Velay A, Schvoerer E, Trimoulet P, Fleury H, Bouvier-Alias M, Brochot E, Duverlie G, Maylin S, Gouriou S, Pawlotsky JM, Morand P. 2015. Naturally occurring resistance-associated variants of hepatitis C virus protease inhibitors in poor responders to pegylated interferon-ribavirin. J Clin Microbiol 53:2195–2202.
53. Lawitz E, Matusow G, De Jesus E, Yoshida E, Felizarta F, Ghalib R, Godofsky E, Herring R, Poleynard G, Sheikh A, Tobias H, Kugelmas M, Kalmeijer R, Peeters M, Lenz O, Fevery B, Rosa G, Scott J, Sinha R, Witek J. 2015a. A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or—Experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2. J Hepatol 62: abstract LP04.
54. Lawitz EJ, Gruener D, Hill JM, Marbury T, Moorehead L, Mathias A, Cheng G, Link JO, Wong KA, Mo H, McHutchison JG, Brainard DM. 2012. A phase 1,randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885,an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 57:24–31.
55. Lawitz E, Flamm S, Yang JC, Pang PS, Zhu Y, Svarovskaia E, McHutchison JG, Wyles D, Pockros P. 2015b. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosabuvir for 24 weeks. J Hepatol 62: abstract O005.
56. Lenz O, Verbinnen T, Lin TI, Vijgen L, Cummings MD, Lindberg J, Berke JM, Dehertogh P, Fransen E, Scholliers A, Vermeiren K, Ivens T, Raboisson P, Edlund M, Storm S, Vrang L, de Kock H, Simmen KA. 2010. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 54:1878–1887.
57. Lenz O, Verbinnen T, Fevery B, Tambuyzer L, Vijgen L, Peeters M, Buelens A, Ceulemans H, Beumont M, Picchio G, De Meyer S. 2015. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. J Hepatol 62:1008–1014.
58. Lindström I, Kjellin M, Palanisamy N, Bondeson K, Wesslén L, Lannergard A, Lennerstrand J. 2015. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden. Infect Dis 47:555–562.
59. Liu R, Curry S, McMonagle P, Yeh WW, Ludmerer SW, Jumes PA, Marshall WL, Kong S, Ingravallo P, Black S, Pak I, DiNubile MJ, Howe AY. 2015. Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir. Antimicrob Agents Chemother 59:6922–6929.
60. Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, McPhee F, Mo H, Parkin N, Pilot-Matias T, Miller V. 2015. Hepatitis C virus drug resistance-associated substitutions: State of the art summary. Hepatology 62:1623–1632.
61. McPhee F, Friborg J, Levine S, Chen C, Falk P, Yu F, Hernandez D, Lee MS, Chaniewski S, Sheaffer AK, Pasquinelli C. 2012. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother 56:3670–3681.
62. McPhee F, Hernandez D, Yu F, Ueland J, Monikowski A, Carifa A, Falk P, Wang C, Fridell R, Eley T, Zhou N, Gardiner D. 2013. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology 58:902–911.
63. McPhee F, Hernandez D, Zhou N, Yu F, Ueland J, Monikowski A, Chayama K, Toyota J, Izumi N, Yokosuka O, Kawada N, Osaki Y, Hughes EA, Watanabe H, Ishikawa H, Kumada H. 2014. Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b. Antivir Ther 19:479–490.
64. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. 2013. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333–1342.
65. Nagpal N, Goyal S, Wahi D, Jain R, Jamal S, Singh A, Rana P, Grover A. 2015. Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease. Gene 570:115–121.
66. Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. 2014. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol 20:2902–2912.
67. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. 1998. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103–107.
68. Ogata N, Alter HJ, Miller RH, Purcell RH. 1991. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci USA 88:3392–3396.
69. Orland JR, Wright TL, Cooper S. 2001. Acute hepatitis C. Hepatology 33:321–327.
70. Paolucci S, Fiorina L, Mariani B, Gulminetti R, Novati S, Barbarini G, Bruno R, Baldanti F. 2013. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients. Virol J 10:355.
71. Paolucci S, Fiorina L, Mariani B, Landini V, Gulminetti R, Novati S, Maserati R, Barbarini G, Bruno R, Baldanti F. 2015. Development and persistence of DAA resistance associated mutations in patients failing HCV treatment. J Clin Virol 72:114–118.
72. Pilot-Matias T, Tripathi R, Cohen D, Gaultier I, Dekhtyar T, Lu L, Reisch T, Irvin M, Hopkins T, Pithawalla R, Middleton T, Ng T, McDaniel K, Or YS, Menon R, Kempf D, Molla A, Collins C. 2015. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother 59:988–997.
73. Plaza Z, Soriano V, Vispo E, Gonzalez M, Barreiro P, Seclén E, Poveda E. 2012. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor. Antivir Ther 17:921–926.
74. Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. 2011. Boceprevir for untreated chronic HCV genotype 1 infection. SPRINT-2 investigators. N Engl J Med 364:1195–1206.
75. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, Forns X, Lovell SS, Da Silva-Tillmann B, Collins CA, Campbell AL, Podsadecki T, Bernstein B. 2014. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 370:1973–1982.
76. Poordad F, Bennett M, Sepe TE, Cohen E, Reindollar R, Everson GT, Phillips RW, Siddique A, Sullivan G, Box TD, Fu B, Pilot-Matias T, Abunimeh M, Cohen DE, Younes Z. 2015. Retreatment of HCV genotype 1 DAA-failures with ombitasvir/paritaoprevir/r, dasabuvir and sofosbuvir. Hepatology 62. abstract LB-20.
77. Premoli C, Aghemo A. 2015. Directly acting antivirals against hepatitis C virus: Mechanisms of action and impact of resistant associated variants. Minerva Gastroenterol Dietol 62:76–87.
78. Qiu P, Sanfiorenzo V, Curry S, Guo Z, Liu S, Skelton A, Xia E, Cullen C, Ralston R, Greene J, Tong X. 2009. Identification of HCV protease inhibitor resistance mutations by selection pressure-based method. Nucleic Acids Res 37:e74.
79. Reddy KR, Bourlière M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, Lawitz E, Marcellin P, Welzel TM, Hyland R, Ding X, Yang J, Knox S, Pang P, Dvory-Sobol H, Subramanian GM, Symonds W, McHutchison JG, Mangia A, Gane E, Mizokami M, Pol S, Afdhal N. 2015. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology 62:79–86.
80. Rudolf K, Beran F, Pyle AM. 2008. Hepatitis C viral NS3-4A protease activity is enhanced by the NS3 helicase. J Biol Chem 283:29929–29937.
81. Ruggiero T, Proietti A, Boglione L, Milia MG, Allice T, Burdino E, Orofino G, Bonora S, Di Perri G, Ghisetti V. 2015. Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: Single-centre experience. Arch Virol 160:2881–2885.
82. Rumi MG, De Filippi F, La Vecchia C, Donato MF, Gallus S, Del Ninno E, Colombo M. 2005. Hepatitis C reactivation in patients with chronic infection with genotype 1b and 2c: A retrospective cohort study of 206 untreated patients. Gut 54:402–406.
83. Ruta S, Cernescu C. 2015. Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes. World J Gastroenterol 21:10811–10823.
84. Sagnelli E, Pasquale G, Coppola N, Scarano F, Marrocco C, Scolastico C, Santantonio T, Gentile A, Piccinino F. 2014. Influence of chronic coinfection with hepatitis B and C virus on liver histology. Infection 32:144–148.
85. Sagnelli E, Coppola N, Marrocco C, Coviello G, Battaglia M, Messina V, Rossi G, Sagnelli C, Scolastico C, Filippini P. 2005. Diagnosis of HCV related acute hepatitis by serial determination of IgM anti-HCV titres. J Hepatol 42:646–651.
86. Sagnelli E, Pisaturo M, Stanzione M, Messina V, Alessio L, Sagnelli C, Starace M, Pasquale G, Coppola N. 2013. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clin Gastroenterol Hepatol 11:1174–1180.
87. Sagnelli E, Santantonio T, Coppola N, Fasano M, Pisaturo M, Sagnelli C. 2014a. Acute hepatitis C: Clinical and laboratory diagnosis, course of the disease, treatment. Infection 42:601–610.
88. Sagnelli E, Sagnelli C, Pisaturo M, Coppola N. 2014b. Hepatic flares in chronic hepatitis C: Spontaneous exacerbation vs hepatotropic viruses superinfection. World J Gastroenterol 20:6707–6715.
89. Sagnelli E, Pisaturo M, Martini S, Sagnelli C, Filippini P, Coppola N. 2014c. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection. Expert Opin Pharmacother 15:1337–1349.
90. Sarrazin C, Dvory-Sobol H, Svarovskaia ES, Doehle B, McCarville JF, Pang PS, Afdhal NH, Kowdley KV, Gane EJ, Lawitz E, McHutchison JG, Miller MD, Mo H. 2014. Baseline and post-baseline resistance analyses of phase 2/3 studies of ledipasvir/sofosbuvir ± RBV. Hepatology 60: abstract 1926.
91. Sarrazin C. 2015. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepato 15:629–637.
92. Schnell G, Tripathi R, Beyer J, Reisch T, Krishnan P, Lu L, Dekhtyar T, Hall C, Vilchez RA, Pilot-Matias T, Collins C. 2015. Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir. Antimicrob Agents Chemother 59:6807–6815.
93. Seeff LB. 2002. Natural history of chronic hepatitis C. Hepatology 36:S35–46.
94. Sheen IS, Liaw YF, Lin DY, Chu CM. 1996. Acute exacerbations in chronic hepatitis C: A clinicopathological and prognostic study. J Hepatol 24:525–525.
95. Shindo H, Maekawa S, Komase K, Sueki R, Miura M, Kadokura M, Shindo K, Amemiya F, Kitamura T, Nakayama Y, Inoue T, Sakamoto M, Okada S, Asahina Y, Izumi N, Honda M, Kaneko S, Enomoto N. 2012. Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients. Hepatol Int 6:482–490.
96. Sims KD, Lemm J, Eley T, Liu M, Berglind A, Sherman D, Lawitz E, Vutikullird AB, Tebas P, Gao M, Pasquinelli C, Grasela DM. 2014. Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection. Antimicrob Agents Chemother 58:3496–3503.
97. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. 2014. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource. Hepatology 59:318–327.
98. Smith MA, Regal RE, Mohammad RA. 2016. Daclatasvir: A NS5A replication complex inhibitor for hepatitis C infection. Ann Pharmacother 50:39–46.
99. Soumana DI, Ali A, Schiffer CA. 2014. Structural analysis of asunaprevir resistance in HCV NS3/4A protease. ACS Chem Biol 9:2485–2490.
100. Suzuki F, Sezaki H, Akuta N, Suzuki Y, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Watahiki S, Miyakawa Y, Kumada H. 2012. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol 54:352–354.
101. Svarovskaia ES, Dvory-Sobol H, Parkin N, Hebner C, Gontcharova V, Martin R, Ouyang W, Han B, Xu S, Ku K, Chiu S, Gane E, Jacobson IM, Nelson DR, Lawitz E, Wyles DL, Bekele N, Brainard D, Symonds WT, McHutchison JG, Miller MD, Mo H. 2014. Infrequent development of resistance in genotype 1–6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis 213:1240–1247.
102. Svarovskaia ES, Gane E, Dvory-Sobol H, Martin R, Doehle B, Hedskog C, Jacobson IM, Nelson DR, Lawitz E, Brainard DM, McHutchison JG, Miller MD, Mo H. 2016. L159F and V321A sofosbuvir-associated hepatitis C virus NS5B substitutions. J Infect Dis In press.
103. Vallet S, Viron F, Henquell C, Le Guillou-Guillemette H, Lagathu G, Abravanel F, Trimoulet P, Soussan P, Schvoerer E, Rosenberg A, Gouriou S, Colson P, Izopet J, Payan C. 2011. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1–5. Antivir Ther 16:1093–1102.
104. Vazquez-Chacon C, Martinez-Guarneros A, Carpio-Pedroza JC, Fonseca-Coronado S, Cruz-Rivera M. 2014. Hepatitis C virus molecular evolution: Transmission, disease progression and antiviral therapy. World J Gastroenterol 20:15992–16013.
105. Wang C, Jia L, O'Boyle DR, Sun JH, 2nd, Rigat K, Valera L, Nower P, Huang X, Kienzle B, Roberts S, Gao M, Fridell RA. 2014. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: Implications for cross-genotype activity. Antimicrob Agents Chemother 58:5155–5563.
106. Wang Y, Rao HY, Xie XW, Wei L. 2015. Direct-acting antiviral agents resistance-associated polymorphisms in chinese treatment-naïve patients infected with genotype 1b hepatitis C virus. Chin Med 128:2625–2631.
107. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. 2014. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370:1604–1614.
108. Zeuzem S, Mizokami M, Pianko S, Mangia A, Han K, Martin R, Svarovskaia ES, Dvory-Sobol H, Doehle B, Pang PS, Knox SJ, McHutchison JG, Brainard DM, Mo Miller MD, Chuang H, Jacobson W, Dore IM, Sulkowski G. 2015. Prevalence of pre-treatment NS5A resistance associated variants in genotype 1 patients across different regions using deep sequencing and effect on treatment outcome with LDV/SOF. Hepatology 62: abstract 91.